U.S. markets closed

AtriCure, Inc. (ATRC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
63.73+1.08 (+1.72%)
At close: 4:00PM EST

63.73 0.00 (0.00%)
After hours: 4:01PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close62.65
Bid63.69 x 1200
Ask75.00 x 900
Day's Range59.94 - 63.84
52 Week Range23.17 - 68.00
Avg. Volume403,851
Market Cap2.904B
Beta (5Y Monthly)1.02
PE Ratio (TTM)N/A
EPS (TTM)-1.14
Earnings DateApr 27, 2021 - May 03, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est70.14
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference
    Business Wire

    AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference

    AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Oppenheimer 31st Annual Healthcare Conference.

  • AtriCure Inc (ATRC) Q4 2020 Earnings Call Transcript
    Motley Fool

    AtriCure Inc (ATRC) Q4 2020 Earnings Call Transcript

    ATRC earnings call for the period ending December 31, 2020.

  • Benzinga

    AtriCure: Q4 Earnings Insights

    Shares of AtriCure (NASDAQ:ATRC) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 51.35% year over year to ($0.18), which beat the estimate of ($0.28). Revenue of $57,725,000 declined by 5.86% from the same period last year, which missed the estimate of $58,100,000. Guidance Atricure Sees FY21 Adj. EBITDA Loss $10M, Adj. EPS $(1.15), Sales ~$250M Atricure Sees Q1 Sales $55M-$57M vs $59.3M Estimate, Adj. EPS $(0.39)-$(0.36) Conference Call Details Date: Feb 23, 2021 Time: 04:30 PM View more earnings on ATRC ET Webcast URL: https://edge.media-server.com/mmc/p/7888agea Technicals 52-week high: $67.01 52-week low: $23.16 Price action over last quarter: Up 69.55% Company Overview AtriCure Inc an atrial fibrillation solutions company that provides products, professional education, and support for clinical science to reduce the economic and social burden of atrial fibrillation. Its products line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offer a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 23, 2021Earnings Preview: AtriCure© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.